JonesTrading analyst Justin Walsh maintained a Buy rating on Fusion Pharmaceuticals (FUSN – Research Report) on November 8 and set a price target of $10.00. The company’s shares opened today at $2.18.
According to TipRanks, Walsh is an analyst with an average return of -31.1% and a 19.05% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, POINT Biopharma Global, and Plus Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fusion Pharmaceuticals with a $10.00 average price target.
The company has a one-year high of $8.73 and a one-year low of $1.98. Currently, Fusion Pharmaceuticals has an average volume of 105.1K.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FUSN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fusion Pharmaceuticals Inc is a clinical stage bio-pharmaceutical company focused on developing alpha therapeutics for curing cancer.
Read More on FUSN:
- Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates
- Fusion Pharmaceuticals reports Q3 EPS (55c), consensus (50c)
- Fusion Pharmaceuticals names Dmitri Bobilev, M.D. as Chief Medical Officer
- FUSN, CAMP, or IREN: Which “Strong Buy” Penny Stock has Over 200% Upside Potential?